Ptc Therapeutics (PTCT) Operating Expenses (2016 - 2025)
Historic Operating Expenses for Ptc Therapeutics (PTCT) over the last 14 years, with Q3 2025 value amounting to $208.0 million.
- Ptc Therapeutics' Operating Expenses fell 1723.27% to $208.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $1.0 billion, marking a year-over-year decrease of 306.95%. This contributed to the annual value of $1.1 billion for FY2024, which is 1945.61% down from last year.
- Per Ptc Therapeutics' latest filing, its Operating Expenses stood at $208.0 million for Q3 2025, which was down 1723.27% from $213.8 million recorded in Q2 2025.
- Ptc Therapeutics' Operating Expenses' 5-year high stood at $423.4 million during Q2 2023, with a 5-year trough of $205.9 million in Q1 2025.
- Over the past 5 years, Ptc Therapeutics' median Operating Expenses value was $251.3 million (recorded in 2024), while the average stood at $272.3 million.
- As far as peak fluctuations go, Ptc Therapeutics' Operating Expenses surged by 6416.08% in 2023, and later crashed by 4639.86% in 2024.
- Ptc Therapeutics' Operating Expenses (Quarter) stood at $250.0 million in 2021, then skyrocketed by 47.13% to $367.8 million in 2022, then dropped by 18.09% to $301.2 million in 2023, then grew by 24.67% to $375.6 million in 2024, then tumbled by 44.62% to $208.0 million in 2025.
- Its last three reported values are $208.0 million in Q3 2025, $213.8 million for Q2 2025, and $205.9 million during Q1 2025.